title: Somatostatin receptor scintigraphy for bronchial carcinoid follow-up.
abstract: OBJECTIVE
  Somatostatin receptor scintigraphy (SRS) has been used to diagnose bronchial carcinoids (BC) and is a valuable tool for accurate staging of BC. The aim of this study was to evaluate the role of SRS in restaging BC and following patients after treatment.
  
  
  METHODS
  Thirty-one patients (18 male, 13 female) with confirmed BC who were referred during the last 7 years were included. Patients were examined via chest radiograph (12 studies), chest or abdominal computed tomography (CT; 28 scans), chest magnetic resonance imaging (2 scans), and liver ultrasound (5 scans).
  
  
  RESULTS
  Overall, in 22 patients (71%), SRS confirmed the data obtained by other diagnostic procedures (16 negative and 6 positive findings). In 6 patients, SRS showed focal lesions not previously demonstrated. In 2 patients, SRS resolved uncertain findings of CT. In 1 patient, SRS showed fewer lesions compared with CT. In 8 of 31 patients, important diagnostic information obtained by SRS was not revealed by any other imaging procedure.
  
  
  CONCLUSIONS
  Our results indicate that SRS is a reliable, noninvasive method that could be considered the principal follow-up procedure in patients with BC.
authors.affiliation: Nuclear Medicine Unit, Ploivlinico S. Orsola-Malpighi, Università degli Studi, Bologna, Italy. fanti@orsola-malpighi.med.unibo.it
authors.forename: Stefano
authors.initials: S
authors.lastname: Fanti
authors.forename: Mohsen
authors.initials: M
authors.lastname: Farsad
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Battista
authors.forename: Francesco
authors.initials: F
authors.lastname: Monetti
authors.forename: Gian Carlo
authors.initials: GC
authors.lastname: Montini
authors.forename: Arturo
authors.initials: A
authors.lastname: Chiti
authors.forename: Giordano
authors.initials: G
authors.lastname: Savelli
authors.forename: Francesco
authors.initials: F
authors.lastname: Petrella
authors.forename: Alessandro
authors.initials: A
authors.lastname: Bini
authors.forename: Cristina
authors.initials: C
authors.lastname: Nanni
authors.forename: Annadina
authors.initials: A
authors.lastname: Romeo
authors.forename: Roberto
authors.initials: R
authors.lastname: Franchi
authors.forename: Emilio
authors.initials: E
authors.lastname: Bombardieri
authors.forename: Romeo
authors.initials: R
authors.lastname: Canini
authors.forename: Nino
authors.initials: N
authors.lastname: Monetti
mesh_terms: D000328:Adult; D000368:Aged; D001984:Bronchial Neoplasms / Q000175:diagnosis / Q000000981:diagnostic imaging* / Q000378:metabolism* / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging / Q000379:methods; D015282:Octreotide / Q000031:analogs & derivatives* / Q000493:pharmacokinetics*; D004369:Pentetic Acid / Q000031:analogs & derivatives* / Q000493:pharmacokinetics*; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D017481:Receptors, Somatostatin / Q000378:metabolism*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
chemical_list: D019275:Radiopharmaceuticals; D017481:Receptors, Somatostatin; C071632:SDZ 215-811; D004369:Pentetic Acid; D015282:Octreotide